{"classes":[{"categories":[{"measurements":[{"comment":"The median and 95% confidence interval were not estimable due to very less number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"PFS was defined as duration from the date of initial dose of ibrutinib to the date of first documented evidence of disease progression or death, whichever occurred first regardless of the use of subsequent antineoplastic therapy prior to documented disease progression or death. Kaplan-Meier method was used for the analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Treatment naive or relapsed/refractory Waldenstrom's Macroglobulinemia (WM) Japanese participants received ibrutinib 420 milligrams (mg) (3\\*140 mg capsules) orally, once daily, from Day 1 of Week 1 until disease progression or unacceptable toxicity along with rituximab 375 milligrams per square meter (mg/m\\^2) intravenously (IV) weekly for 4 consecutive weeks (Day 1 of Weeks 1 to 4), followed by a second course of once-weekly rituximab for 4 consecutive weeks (from Week 17 to 20) after a 12-week interval.","id":"OG000","title":"Ibrutinib + Rituximab"}],"paramType":"MEDIAN","populationDescription":"All treated analysis set included all enrolled participants who received at least 1 dose of ibrutinib.","reportingStatus":"POSTED","timeFrame":"From the date of initial dose up to 3 years and 5 months","title":"Progression Free Survival (PFS) Assessed by Independent Review Committee","type":"SECONDARY","unitOfMeasure":"months"}